James M Olson

List of Publications by Year
in descending order

132	16,584	25034 57	16650 123
papers	citations	h-index	g-index

138	138	138	19471
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Ex silico engineering of cystine-dense peptides yielding a potent bispecific T cell engager. Science Translational Medicine, 2022, 14, eabn0402.	12.4	3
2	DIPG-58. Therapeutic HDAC targeting in hypermutant CNS tumors. Neuro-Oncology, 2022, 24, i32-i32.	1.2	0
3	Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naÃ¯ve diffuse midline glioma models. Neuro-Oncology, 2021, 23, 376-386.	1.2	43
4	Medulloblastoma recurrence and metastatic spread are independent of colony-stimulating factor 1 receptor signaling and macrophage survival. Journal of Neuro-Oncology, 2021, 153, 225-237.	2.9	15
5	Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma. Genome Medicine, 2021, 13, 103.	8.2	10
6	A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients. Contemporary Clinical Trials Communications, 2021, 23, 100830.	1.1	18
7	Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma. JAMA Oncology, 2021, 7, 1313.	7.1	61
8	Predictors of mortality and tumor recurrence in desmoplastic infantile ganglioglioma and astrocytomaâ€"and individual participant data meta-analysis (IPDMA). Journal of Neuro-Oncology, 2021, 155, 155-163.	2.9	1
9	T Cell Engaging Bispecific Antibodies Produce Durable Response in Mesothelin-Positive Patient-Derived Xenograft Models of Pediatric AML. Blood, 2021, 138, 1280-1280.	1.4	0
10	Functional Precision Medicine Identifies New Therapeutic Candidates for Medulloblastoma. Cancer Research, 2020, 80, 5393-5407.	0.9	38
11	Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Childrenâ€™s Hospital experience. Journal of Neuro-Oncology, 2020, 148, 607-617.	2.9	21
12	Circumventing colistin resistance by combining colistin and antimicrobial peptides to kill colistin-resistant and multidrug-resistant Gram-negative bacteria. Journal of Global Antimicrobial Resistance, 2020, 22, 706-712.	2.2	9
13	A potent peptide-steroid conjugate accumulates in cartilage and reverses arthritis without evidence of systemic corticosteroid exposure. Science Translational Medicine, 2020, 12, .	12.4	27
14	Miniproteins as a Powerful Modality in Drug Development. Trends in Biochemical Sciences, 2020, 45, 332-346.	7.5	39
15	A TfR-Binding Cystine-Dense Peptide Promotes Bloodâ€"Brain Barrier Penetration of Bioactive Molecules. Journal of Molecular Biology, 2020, 432, 3989-4009.	4.2	20
16	Mammalian Surface Display Screening of Diverse Cystine-Dense Peptide Libraries for Difficult-to-Drug Targets. Methods in Molecular Biology, 2020, 2070, 363-396.	0.9	4
17	Histone deposition pathways determine the chromatin landscapes of H3.1 and H3.3 K27M oncohistones. ELife, 2020, 9, .	6.0	42
18	MODL-28. IMMUNE PRIMING WITH INTERFERON-Î“ COMBINED WITH EPIGENETIC MODULATION IN PEDIATRIC BRAIN TUMORS. Neuro-Oncology, 2020, 22, iii416-iii417.	1.2	0

#	Article	IF	Citations
19	A Protocol for the Generation of Treatment-naÃ¯ve Biopsyderived Diffuse Intrinsic Pontine Glioma and Diffuse Midline Glioma Models. , 2020, 1, 158-167.		3
20	DIPG-10. OPTIMAL HDAC INHIBITION IN DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2020, 22, iii288-iii289.	1.2	0
21	Laboratory information management software for engineered mini-protein therapeutic workflow. BMC Bioinformatics, 2019, 20, 343.	2.6	0
22	Simultaneous extraction and analysis of multiple cystine-dense peptides by Î¼SPE and microflow-MS/MS from plasma. Bioanalysis, 2019, 11, 485-493.	1.5	1
23	Single-Cell Transcriptomics in Medulloblastoma Reveals Tumor-Initiating Progenitors and Oncogenic Cascades during Tumorigenesis and Relapse. Cancer Cell, 2019, 36, 302-318.e7.	16.8	96
24	Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. Nature Communications, 2019, 10, 2400.	12.8	37
25	PDTM-09. Yap1 FUNCTION IN SEX-BIASED MEDULLOBLASTOMA FORMATION AND ANTI-TUMOR IMMUNITY. Neuro-Oncology, 2019, 21, vi188-vi188.	1.2	0
26	MRI Features of Histologically Diagnosed Supratentorial Primitive Neuroectodermal Tumors and Pineoblastomas in Correlation with Molecular Diagnoses and Outcomes: A Report from the Childrenâ€™s Oncology Group ACNS0332 Trial. American Journal of Neuroradiology, 2019, 40, 1796-1803.	2.4	11
27	TMIC-48. MACROPHAGE DEPLETION COMBINED WITH RADIATION IN A PRECLINICAL MEDULLOBLASTOMA MODEL. Neuro-Oncology, 2019, 21, vi258-vi258.	1.2	0
28	Recurrent noncoding U1ÂsnRNA mutations drive cryptic splicing in SHH medulloblastoma. Nature, 2019, 574, 707-711.	27.8	129
29	Screening, large-scale production and structure-based classification of cystine-dense peptides. Nature Structural and Molecular Biology, 2018, 25, 270-278.	8.2	44
30	Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation. Leukemia, 2018, 32, 1239-1243.	7.2	57
31	A modified gene trap approach for improved high-throughput cancer drug discovery. Oncogene, 2018, 37, 4226-4238.	5.9	5
32	DIPG-35. A NOVEL HDAC INHIBITOR IN NEW PATIENT-DERIVED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) MODELS. Neuro-Oncology, 2018, 20, i56-i56.	1.2	3
33	PCLN-04. BRAIN TUMOR PATIENT DERIVED ORTHOTOPIC XENOGRAFTS INDUCE TUMORS OF MOUSE ORIGIN. Neuro-Oncology, 2018, 20, i155-i155.	1.2	1
34	Automated in situ chromatin profiling efficiently resolves cell types and gene regulatory programs. Epigenetics and Chromatin, 2018, 11, 74.	3.9	53
35	A biobank of patient-derived pediatric brain tumor models. Nature Medicine, 2018, 24, 1752-1761.	30.7	124
36	PCLN-05. A BIOBANK OF PATIENT-DERIVED MOLECULARLY CHARACTERIZED ORTHOTOPIC PEDIATRIC BRAIN TUMOR MODELS FOR PRECLINICAL RESEARCH. Neuro-Oncology, 2018, 20, i155-i155.	1.2	0

#	Article	IF	Citations
37	NSRG-15. FIRST IN HUMAN USE OF CANVAS IMAGING SYSTEM FOR VISUALIZATION OF TOZULERISTIDE-INDUCED TUMOR FLUORESCENCE. Neuro-Oncology, 2018, 20, i148-i148.	1.2	0
38	Huron-to-Erie Water Quality Data Platform. Environmental Processes, 2018, 5, 465-481.	3.5	0
39	Desmoplastic Infantile Ganglioglioma/Astrocytoma (DIG/DIA) Are Distinct Entities with Frequent BRAFV600 Mutations. Molecular Cancer Research, 2018, 16, 1491-1498.	3.4	39
40	Pacifastin-derived Peptides Target Tumors for Use in In Vivo Imaging. Anticancer Research, 2018, 38, 51-60.	1.1	0
41	Loss of Pin1 Suppresses Hedgehog-Driven Medulloblastoma Tumorigenesis. Neoplasia, 2017, 19, 216-225.	5.3	7
42	Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell, 2017, 31, 737-754.e6.	16.8	836
43	Multidrug Analyses in Patients Distinguish Efficacious Cancer Agents Based on Both Tumor Cell Killing and Immunomodulation. Cancer Research, 2017, 77, 2869-2880.	0.9	17
44	Nonclinical Profile of BLZ-100, a Tumor-Targeting Fluorescent Imaging Agent. International Journal of Toxicology, 2017, 36, 104-112.	1.2	41
45	PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. Cancer Research, 2017, 77, e62-e66.	0.9	92
46	Inhibition of CDK4/6 by Palbociclib Significantly Extends Survival in Medulloblastoma Patient-Derived Xenograft Mouse Models. Clinical Cancer Research, 2017, 23, 5802-5813.	7.0	74
47	Mammalian display screening of diverse cystine-dense peptides for difficult to drug targets. Nature Communications, 2017, 8, 2244.	12.8	56
48	ZNF131 suppresses centrosome fragmentation in glioblastoma stem-like cells through regulation of HAUS5. Oncotarget, 2017, 8, 48545-48562.	1.8	19
49	Predicting responses to chemotherapy in the context that matters - the patient. Molecular and Cellular Oncology, 2016, 3, e1057315.	0.7	2
50	Accurate de novo design of hyperstable constrained peptides. Nature, 2016, 538, 329-335.	27.8	327
51	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. Journal of Clinical Oncology, 2016, 34, 2468-2477.	1.6	160
52	Fluorescence Identification of Head and Neck Squamous Cell Carcinoma and High-Risk Oral Dysplasia With BLZ-100, a Chlorotoxin-Indocyanine Green Conjugate. JAMA Otolaryngology - Head and Neck Surgery, 2016, 142, 330.	2.2	35
53	HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC- Driven Medulloblastoma. Cancer Cell, 2016, 29, 311-323.	16.8	204
54	Successful Translation of Fluorescence Navigation During Oncologic Surgery: A Consensus Report. Journal of Nuclear Medicine, 2016, 57, 144-150.	5.0	125

#	Article	IF	Citations
55	Image-Guided Tumor Resection. Cancer Journal (Sudbury, Mass), 2015, 21, 206-212.	2.0	16
56	Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study. Child's Nervous System, 2015, 31, 1283-1289.	1.1	41
57	Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells. Cell Reports, 2015, 13, 2425-2439.	6.4	146
58	Molecular Pathways: Regulation and Targeting of Kinetochoreâ€“Microtubule Attachment in Cancer. Clinical Cancer Research, 2015, 21, 233-239.	7.0	23
59	Efficacy of cabazitaxel in mouse models of pediatric brain tumors. Neuro-Oncology, 2015, 17, 107-115.	1.2	31
60	A technology platform to assess multiple cancer agents simultaneously within a patientâ€™s tumor. Science Translational Medicine, 2015, 7, 284ra58.	12.4	76
61	Preclinical Validation of the Utility of BLZ-100 in Providing Fluorescence Contrast for Imaging Spontaneous Solid Tumors. Cancer Research, 2015, 75, 4283-4291.	0.9	76
62	BuGZ Is Required for Bub3 Stability, Bub1 Kinetochore Function, and Chromosome Alignment. Developmental Cell, 2014, 28, 282-294.	7.0	64
63	Pemetrexed and Gemcitabine as Combination Therapy for the Treatment of Group3 Medulloblastoma. Cancer Cell, 2014, 25, 516-529.	16.8	128
64	Cytogenetic Prognostication Within Medulloblastoma Subgroups. Journal of Clinical Oncology, 2014, 32, 886-896.	1.6	263
65	Therapeutic Opportunities for Medulloblastoma Come of Age. Cancer Cell, 2014, 25, 267-269.	16.8	4
66	MyoD Is a Tumor Suppressor Gene in Medulloblastoma. Cancer Research, 2013, 73, 6828-6837.	0.9	21
67	Canonical <scp>TGF</scp>â€Î² Pathway Activity Is a Predictor of <scp>SHH</scp>â€Driven Medulloblastoma Survival and Delineates Putative Precursors in Cerebellar Development. Brain Pathology, 2013, 23, 178-191.	4.1	26
68	Correction to Chemical Re-engineering of Chlorotoxin Improves Bioconjugation Properties for Tumor Imaging and Targeted Therapy. Journal of Medicinal Chemistry, 2013, 56, 9807-9807.	6.4	1
69	Cancer-Specific Requirement for BUB1B/BUBR1 in Human Brain Tumor Isolates and Genetically Transformed Cells. Cancer Discovery, 2013, 3, 198-211.	9.4	78
70	Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5A. Genes and Development, 2013, 27, 1032-1045.	5.9	114
71	Fundamental differences in promoter CpG island DNA hypermethylation between human cancer and genetically engineered mouse models of cancer. Epigenetics, 2013, 8, 1254-1260.	2.7	16
72	Sonic Hedgehog-Induced Histone Deacetylase Activation Is Required for Cerebellar Granule Precursor Hyperplasia in Medulloblastoma. PLoS ONE, 2013, 8, e71455.	2.5	37

#	Article	IF	Citations
73	The molecular classification of medulloblastoma. Current Opinion in Pediatrics, 2012, 24, 33-39.	2.0	55
74	A Distinct Smoothened Mutation Causes Severe Cerebellar Developmental Defects and Medulloblastoma in a Novel Transgenic Mouse Model. Molecular and Cellular Biology, 2012, 32, 4104-4115.	2.3	39
75	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature, 2012, 488, 49-56.	27.8	761
76	Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 7859-7864.	7.1	116
77	Chemical Re-engineering of Chlorotoxin Improves Bioconjugation Properties for Tumor Imaging and Targeted Therapy. Journal of Medicinal Chemistry, 2011, 54, 782-787.	6.4	91
78	In Vivo Bio-imaging Using Chlorotoxin-based Conjugates. Current Pharmaceutical Design, 2011, 17, 4362-4371.	1.9	72
79	NeuroD Factors Regulate Cell Fate and Neurite Stratification in the Developing Retina. Journal of Neuroscience, 2011, 31, 7365-7379.	3.6	94
80	Integrative Genomic Analysis of Medulloblastoma Identifies a Molecular Subgroup That Drives Poor Clinical Outcome. Journal of Clinical Oncology, 2011, 29, 1424-1430.	1.6	609
81	Genome-Wide Analyses Identify Recurrent Amplifications of Receptor Tyrosine Kinases and Cell-Cycle Regulatory Genes in Diffuse Intrinsic Pontine Glioma. Journal of Clinical Oncology, 2011, 29, 3999-4006.	1.6	286
82	Environmental Enrichment Reduces Neuronal Intranuclear Inclusion Load But Has No Effect on Messenger RNA Expression in a Mouse Model of Huntington Disease. Journal of Neuropathology and Experimental Neurology, 2010, 69, 817-827.	1.7	33
83	DNA methylation of developmental genes in pediatric medulloblastomas identified by denaturation analysis of methylation differences. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 234-239.	7.1	59
84	DTI fiber tracking to differentiate demyelinating diseases from diffuse brain stem glioma. NeuroImage, 2010, 52, 217-223.	4.2	43
85	Transcriptional inhibition of REST by NeuroD2 during neuronal differentiation. Molecular and Cellular Neurosciences, 2010, 44, 178-189.	2.2	18
86	Rapid Pharmacokinetic and Biodistribution Studies Using Cholorotoxin-Conjugated Iron Oxide Nanoparticles: A Novel Non-Radioactive Method. PLoS ONE, 2010, 5, e9536.	2.5	85
87	PEIâ€“PEGâ€“Chitosanâ€Copolymerâ€Coated Iron Oxide Nanoparticles for Safe Gene Delivery: Synthesis, Complexation, and Transfection. Advanced Functional Materials, 2009, 19, 2244-2251.	14.9	359
88	Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA). Journal of Neuro-Oncology, 2008, 87, 133-141.	2.9	67
89	E protein dosage influences brain development more than family member identity. Journal of Neuroscience Research, 2008, 86, 1472-1481.	2.9	38
90	Methylation of PTCH1, the Patched-1 gene, in a panel of primary medulloblastomas. Cancer Genetics and Cytogenetics, 2008, 180, 47-50.	1.0	40

#	Article	IF	Citations
91	The Smo/Smo Model: Hedgehog-Induced Medulloblastoma with 90% Incidence and Leptomeningeal Spread. Cancer Research, 2008, 68, 1768-1776.	0.9	155
92	Conservation of Regional Gene Expression in Mouse and Human Brain. PLoS Genetics, 2007, 3, e59.	3.5	91
93	Huntingtin Interacting Proteins Are Genetic Modifiers of Neurodegeneration. PLoS Genetics, 2007, 3, e82.	3.5	368
94	Assessing Bias in Experiment Design for Large Scale Mass Spectrometry-based Quantitative Proteomics. Molecular and Cellular Proteomics, 2007, 6, 1741-1748.	3.8	52
95	Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Human Molecular Genetics, 2007, 16, 1845-1861.	2.9	304
96	Expression Profiling of Huntington's Disease Models Suggests That Brain-Derived Neurotrophic Factor Depletion Plays a Major Role in Striatal Degeneration. Journal of Neuroscience, 2007, 27, 11758-11768.	3.6	197
97	Tumor Paint: A Chlorotoxin:Cy5.5 Bioconjugate for Intraoperative Visualization of Cancer Foci. Cancer Research, 2007, 67, 6882-6888.	0.9	384
98	Regional and cellular gene expression changes in human Huntington's disease brain. Human Molecular Genetics, 2006, 15, 965-977.	2.9	696
99	Nervous system cancer models: Medulloblastoma. Drug Discovery Today: Disease Models, 2006, 3, 167-174.	1.2	1
100	Regulation of Thalamocortical Patterning and Synaptic Maturation by NeuroD2. Neuron, 2006, 49, 683-695.	8.1	104
101	Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma. Journal of Neuro-Oncology, 2006, 79, 259-270.	2.9	48
102	Congenital Hypothyroidism (Cretinism) in neuroD2-Deficient Mice. Molecular and Cellular Biology, 2006, 26, 4311-4315.	2.3	8
103	Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. Human Molecular Genetics, 2006, 15, 273-285.	2.9	127
104	N-myc Is an Essential Downstream Effector of Shh Signaling during both Normal and Neoplastic Cerebellar Growth. Cancer Research, 2006, 66, 8655-8661.	0.9	157
105	Cisplatin-based chemotherapy followed by focal, reduced-dose irradiation for pediatric primary central nervous system germinomas. Journal of Pediatric Hematology/Oncology, 2006, 28, 36-9.	0.6	9
106	Significance testing for small microarray experiments. Statistics in Medicine, 2005, 24, 2281-2298.	1.6	59
107	Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease. Human Molecular Genetics, 2005, 14, 3065-3078.	2.9	108
108	Dysfunction of the Cholesterol Biosynthetic Pathway in Huntington's Disease. Journal of Neuroscience, 2005, 25, 9932-9939.	3.6	236

#	Article	IF	Citations
109	Gene expression in Huntington's disease skeletal muscle: a potential biomarker. Human Molecular Genetics, 2005, 14, 1863-1876.	2.9	150
110	The dosage of the neuroD2 transcription factor regulates amygdala development and emotional learning. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 14877-14882.	7.1	42
111	The SmoA1 Mouse Model Reveals That Notch Signaling Is Critical for the Growth and Survival of Sonic Hedgehog-Induced Medulloblastomas. Cancer Research, 2004, 64, 7794-7800.	0.9	409
112	Regulation of neuroD2 expression in mouse brain. Developmental Biology, 2004, 265, 234-245.	2.0	29
113	p38 MAP kinase: a convergence point in cancer therapy. Trends in Molecular Medicine, 2004, 10, 125-129.	6.7	289
114	Genetic heterogeneity of stably transfected cell lines revealed by expression profiling with oligonucleotide microarrays. Journal of Cellular Biochemistry, 2003, 90, 1068-1078.	2.6	14
115	BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nature Medicine, 2003, 9, 1033-1038.	30.7	169
116	Altered transcriptional regulation in cells expressing the expanded polyglutamine androgen receptor. Human Molecular Genetics, 2002, 11, 1967-1976.	2.9	132
117	Estimating the statistical significance of gene expression changes observed with oligonucleotide arrays. Human Molecular Genetics, 2002, 11, 2207-2221.	2.9	14
118	Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Human Molecular Genetics, 2002, 11, 1911-1926.	2.9	327
119	Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. Human Molecular Genetics, 2002, 11, 1953-1965.	2.9	189
120	Evaluating test statistics to select interesting genes in microarray experiments. Human Molecular Genetics, 2002, 11, 2223-2232.	2.9	22
121	Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease. Human Molecular Genetics, 2002, 11, 1939-1951.	2.9	129
122	Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. Human Molecular Genetics, 2002, 11, 1927-1937.	2.9	185
123	A regression-based method to identify differentially expressed genes in microarray time course studies and its application in an inducible Huntington's disease transgenic model. Human Molecular Genetics, 2002, 11, 1977-1985.	2.9	62
124	Medulloblastoma Growth Inhibition by Hedgehog Pathway Blockade. Science, 2002, 297, 1559-1561.	12.6	760
125	Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature, 2002, 415, 436-442.	27.8	2,154
126	NeuroD2 Is Necessary for Development and Survival of Central Nervous System Neurons. Developmental Biology, 2001, 234, 174-187.	2.0	149

#	Article	IF	Citations
127	Therapeutic opportunities in polyglutamine disease. Nature Medicine, 2001, 7, 419-423.	30.7	71
128	An Efficient and Robust Statistical Modeling Approach to Discover Differentially Expressed Genes Using Genomic Expression Profiles. Genome Research, 2001, 11, 1227-1236.	5.5	272
129	The Hereditary Disease Array Group (HDAG) - Microarrays, Models and Mechanisms : A Collaboration Update. Current Genomics, 2001, 2, 221-229.	1.6	3
130	Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Human Molecular Genetics, 2000, 9, 1259-1271.	2.9	645
131	Treatment of diencephalic syndrome with chemotherapy. , 1998, 83, 166-172.		65
132	Localization of the peripheral-type benzodiazepine binding site to mitochondria of human glioma cells. Journal of Neuro-Oncology, 1992, 13, 35-42.	2.9	15